Eikon Therapeutics News and Resources

Eikon Therapeutics, a pivotal-stage biotechnology company, has announced the initial closing of its $350.7 million Series D financing to advance its drug discovery and development efforts. Since its founding in 2019, the company has privately raised more than $1.1 billion to support its mission